A multifunctional natural killer (NK) cell engager that binds NKp46 and CD123

JP2024501539A5Active Publication Date: 2024-11-07SANOFI SA(FR) +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023539973
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-18
Filing Date
2021-12-30
Publication Date
2024-11-07
Estimated Expiration
2041-12-30

Smart Images

  • Figure 00000100_0000
    Figure 00000100_0000
  • Figure 00000100_0001
    Figure 00000100_0001
  • Figure 00000100_0002
    Figure 00000100_0002
Patent Text Reader

Abstract

The present disclosure relates to a multifunctional binding protein comprising a first and a second antigen binding domain (ABD) and all or a portion of an immunoglobulin Fc region or a variant thereof, wherein the first ABD specifically binds to human CD123, the second ABD specifically binds to human NKp46, and all or a portion of the immunoglobulin Fc region or a variant thereof binds to a human Fc-gamma receptor. The present disclosure also relates to methods of making said binding proteins, compositions thereof, and uses thereof, including for the treatment or prevention of proliferative disorders, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Need to check novelty before this filing date? Find Prior Art

Claims

1. A binding protein comprising first and second antigen binding domains (ABDs) and all or a portion of an immunoglobulin Fc region or a variant thereof, wherein said ABDs each comprise an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of the VH and VL comprising three complementarity determining regions (CDR-1 through CDR-3); (i) the first ABD specifically binds to human CD123; and VH1 comprising CDR-H1, H2, and H3 comprising the amino acid sequences of SEQ ID NOs: 1 to 3, respectively, or comprising the amino acid sequences of SEQ ID NOs: 4 to 6, respectively; and VL1 comprising CDR-L1, L2, and L3 comprising the amino acid sequences of SEQ ID NOs: 7-9, respectively, or the amino acid sequences of SEQ ID NOs: 10-12, respectively. Including; (ii) the second ABD specifically binds to human NKp46; and The amino acid sequences of SEQ ID NOs: 13 to 15, respectively; The amino acid sequences of SEQ ID NOs: 16 to 18, respectively; The amino acid sequences of SEQ ID NOs: 19 to 21, respectively; The amino acid sequences of SEQ ID NOs: 22 to 24, respectively; or The amino acid sequences of SEQ ID NOs: 16, 25, and 26, respectively; VH2 comprising CDR-H1, 2, and 3, and The amino acid sequences of SEQ ID NOs:27 to 29, respectively; The amino acid sequences of SEQ ID NOs: 30 to 32, respectively; The amino acid sequences of SEQ ID NOs: 33 to 35, respectively; The amino acid sequences of SEQ ID NOs: 36 to 38, respectively; or The amino acid sequences of SEQ ID NOs: 39, 31, and 40, respectively; VL2 comprising CDR-L1, 2, and 3 Including, The immunoglobulin Fc region or a variant thereof is a human Fc-γ receptor. Binds to the body, Binding proteins.

2. Three polypeptide chains (I), (II), and (III) form two ABDs defined below: Light chain variable domain 1A (V 1A ) - light chain constant domain 1A (C 1A ) - Hinge 1 - (C H 2-C H 3) A (I) Heavy chain variable domain 1B (V 1B ) - heavy chain constant domain (C 1B ) - Hinge 2 - (C H 2-C H 3) B -L 1 - Heavy chain variable domain 2A (V 2A ) - heavy chain constant domain 2A (C 2A ) - Hinge 3 (II) Light chain variable domain 2B (V 2B ) - light chain constant domain 2B (C 2B ) (III) wherein: V 1A and V 1B is a bond pair V 1 (V H1 / V L1 ) to form; V 2A and V 2B is a bond pair V 2 (V H2 / V L2 ) to form; C 1A and C 1B is against C 1 (C H 1 / C L ) and C 2A and C 2B is against C 2 (C H 1 / C L ) and C H 1 is immunoglobulin heavy chain constant domain 1, C Lis an immunoglobulin light chain constant domain; Hinge 1 , hinge 2 , and hinge 3 are the same or different and comprise all or part of an immunoglobulin hinge region; (C H 2-C H 3) A and (C H 2-C H 3) B are identical or different and are the same as or different from the immunoglobulin heavy chain constant domain 2 (C H 2) and immunoglobulin heavy chain constant domain 3 (C H 3) includes; L 1 is an amino acid linker, The binding protein of claim 1.

3. C 1B is an immunoglobulin heavy chain constant domain 1 (C H 1) and C 2A is an immunoglobulin heavy chain constant domain 1 (C H 1) and C L is an immunoglobulin kappa light chain constant domain (C κ ) (C H 2-C H 3) A comprises the amino acid sequence of SEQ ID NO:69; (C H 2-C H 3) B comprises the amino acid sequence of SEQ ID NO:70; Hinge 1 comprises the amino acid sequence of SEQ ID NO:74; Hinge 2 comprises the amino acid sequence of SEQ ID NO:75; Hinge 3 comprises the amino acid sequence of SEQ ID NO:77; L 1 comprises the amino acid sequence of SEQ ID NO: 76; The binding protein of claim 2.

4. The binding protein of claim 2 , comprising at least two polypeptide chains linked by at least one disulfide bridge.

5. Polypeptide chains (I) and (II) are C 1A and hinge 2 and / or the polypeptide chains (II) and (III) are linked by at least one disulfide bridge between them, 3 and C. 2B The binding protein of claim 4, wherein the binding protein is linked by at least one disulfide bridge between

6. V 1A is V L1 And V 1B is V H1 The binding protein of claim 2 .

7. V 2A is V H2 And V 2B is V L2 The binding protein of claim 2 .

8. - polypeptide (I) consists of the amino acid sequence of SEQ ID NO: 64; - polypeptide (II) consists of the amino acid sequence of SEQ ID NO: 65; - the polypeptide (III) consists of the amino acid sequence of SEQ ID NO: 66, The binding protein of claim 2.

9. 2. The binding protein of claim 1, wherein residue N297 of the Fc region or variant thereof according to EU numbering comprises an N-linked glycosylation, and wherein the Fc region or variant thereof is a human Fc region or variant thereof of an IgG1, IgG2, IgG3, or IgG4 isotype.

10. The binding protein of claim 1, wherein all or a portion of the Fc region or a variant thereof binds to a human CD16A (FcγRIII) polypeptide.

11. (a) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:9; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:28; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:29; (b) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:9; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:30; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:32; (c) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; L1comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:9; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (d) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:9; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:22; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:23; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:24; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38; (e) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:7; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:8; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:9; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; L2 CDR-L1 comprising the amino acid sequence of SEQ ID NO:39; CDR-L2 comprising the amino acid sequence of SEQ ID NO:31; comprising a CDR-L3 comprising the amino acid sequence of SEQ ID NO:40; (f) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:6; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:28; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:29; (g) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:6; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:30; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:31; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:32; (h) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:6; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (i) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:22; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:23; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:24; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37; a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38; (j) V H1 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:4; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:5; a CDR-H3 comprising the amino acid sequence of SEQ ID NO:6; L1 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 12; H2 comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25; a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; L2 comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 39; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 31; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 40; The binding protein of claim 1.

12. (a) V H1 and V L1 comprises the amino acid sequences of SEQ ID NOs: 41 and 43, respectively, or comprises the amino acid sequences of SEQ ID NOs: 42 and 44, respectively; and / or (b) V H2 and V L2 teeth, The amino acid sequences of SEQ ID NOs: 45 and 53, respectively; The amino acid sequences of SEQ ID NOs: 46 and 54, respectively; The amino acid sequences of SEQ ID NOs: 47 and 55, respectively; The amino acid sequences of SEQ ID NOs: 48 and 56, respectively; The amino acid sequences of SEQ ID NOs: 49 and 57, respectively; The amino acid sequences of SEQ ID NOs: 50 and 58, respectively; The amino acid sequences of SEQ ID NOs: 51 and 59, respectively; or Comprising the amino acid sequences of SEQ ID NOs: 52 and 60, respectively; The binding protein of claim 1.

13. (a) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO: 45; L2 comprises the amino acid sequence of SEQ ID NO:53; (b) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO: 46; L2 comprises the amino acid sequence of SEQ ID NO:54; (c) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO: 47; L2 comprises the amino acid sequence of SEQ ID NO:55; (d) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO: 48; L2 comprises the amino acid sequence of SEQ ID NO:56; (e) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO:49; L2 comprises the amino acid sequence of SEQ ID NO:57; (f) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO:50; L2 comprises the amino acid sequence of SEQ ID NO:58; (g) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO:51; L2 comprises the amino acid sequence of SEQ ID NO:59; (h) V H1 comprises the amino acid sequence of SEQ ID NO: 41; L1 comprises the amino acid sequence of SEQ ID NO: 43; H2 comprises the amino acid sequence of SEQ ID NO:52; L2 comprises the amino acid sequence of SEQ ID NO:60; (i) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO: 45; L2 comprises the amino acid sequence of SEQ ID NO:53; (j) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO: 46; L2 comprises the amino acid sequence of SEQ ID NO:54; (k) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO: 47; L2 comprises the amino acid sequence of SEQ ID NO:55; (l) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO: 48; L2 comprises the amino acid sequence of SEQ ID NO:56; (m) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO:49; L2 comprises the amino acid sequence of SEQ ID NO:57; (n) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO:50; L2 comprises the amino acid sequence of SEQ ID NO:58; (o) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO:51; L2 is SEQ ID NO:5 9 amino acid sequence; (p) V H1 comprises the amino acid sequence of SEQ ID NO: 42; L1 comprises the amino acid sequence of SEQ ID NO: 44; H2 comprises the amino acid sequence of SEQ ID NO:52; L2 comprises the amino acid sequence of SEQ ID NO: 60; 13. The binding protein of claim 12.

14. A pharmaceutical composition comprising the binding protein of claim 1 and a pharma- ceutically acceptable carrier.

15. A binding protein comprising first and second antigen binding domains (ABDs) and all or a portion of an immunoglobulin Fc region or a variant thereof, said ABDs each comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of the VH and VL comprising three complementarity determining regions (CDR-1 through CDR-3); (i) the first ABD specifically binds human CD123 and comprises the amino acid sequence of SEQ ID NO: 41; H1 and V comprising the amino acid sequence of SEQ ID NO:

43. L1 Including, (ii) the second ABD specifically binds human NKp46 and comprises the amino acid sequence of SEQ ID NO: 45; H2 and V comprising the amino acid sequence of SEQ ID NO:

53. L2 Including, Binding proteins.

16. 16. The binding protein of claim 15, wherein residue N297 of the Fc region or variant thereof according to EU numbering comprises an N-linked glycosylation, and wherein the Fc region or variant thereof is a human Fc region or variant thereof of an IgG1, IgG2, IgG3, or IgG4 isotype.

17. The binding protein of claim 15, wherein all or a portion of the Fc region or a variant thereof binds to a human CD16A (FcγRIII) polypeptide.

18. 16. A pharmaceutical composition comprising the binding protein of claim 15 and a pharma- ceutically acceptable carrier.

19. A binding protein comprising three polypeptide chains (I), (II), (III) forming a first and a second antigen binding domain (ABD), Polypeptide (I) consists of the amino acid sequence of SEQ ID NO:64; Polypeptide (II) consists of the amino acid sequence of SEQ ID NO:65; Polypeptide (III) consists of the amino acid sequence of SEQ ID NO: 66; Binding proteins.

20. 20. A pharmaceutical composition comprising the binding protein of claim 19 and a pharma- ceutically acceptable carrier.

21. Three polypeptide chains (I), (II), and (III) forming a first and second antigen binding domain (ABD): A polypeptide (I) comprising the amino acid sequence of SEQ ID NO:64; A polypeptide (II) comprising the amino acid sequence of SEQ ID NO:65; and Polypeptide comprising the amino acid sequence of SEQ ID NO:66 (III) A binding protein comprising:

22. 22. A pharmaceutical composition comprising the binding protein of claim 21 and a pharma- ceutically acceptable carrier.